RDM1 plays an oncogenic role in human ovarian carcinoma cells

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1080/21691401.2020.1770267

RDM1 plays an oncogenic role in human ovarian carcinoma cells

Lu Tong & Lihua Wang et al.

Ovarian cancer is one of the deadliest gynecological cancer, with a low overall 5-year survival rate. RDM1, RAD52 motif-containing protein 1, is sensitive to cisplatin, a common chemotherapy drug and it has an important role inDNA damage repair pathway. Until now, the effect of RDM1 in ovarian cancer is undiscovered. Here, clinical data shows that the tumour tissues of ovarian carcinoma patients with higher mRNA and protein expression of RDM1. Knockdown of

Links

DOI PubMed

Journal

Artificial Cells, Nanomedicine, and Biotechnology

Authors

Lu Tong, Wenjiao Cao, Jun Sheng, Enhao Zhu, Ying Yu, Tianying Zhong, Yajun Chen, Lihua Wang

Funding

National Natural Science Foundation of China Grant 81572547 Shanghai Collaborative Innovation Centre for Translational Medicine Grant TM201923 Shanghai Municipal Key Clinical Specialty Grant shslczdzk06302 China Postdoctoral Science Foundation Grant 2019M651434 Foundation of Science Technology Department of Sichuan Province Grant 2018FZ0065